Fortress Biotech, Inc. (NASDAQ:FBIO)
| Market Cap | $63.63M-25.5% |
| Revenue (ttm) | $69.99M+12.3% |
| Net Income | $100.12M+2411.2% |
| EPS | $2.34+907.6% |
| Shares Out | 33.49M |
| PE Ratio | 0.65 |
| Forward PE | 2.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 739,058 |
| Open | $1.86 |
| Previous Close | $1.77 |
| Day's Range | $1.84 - $1.99 |
| 52-Week Range | $1.64 - $4.53 |
| Beta | 1.25 |
| Analysts | Buy |
| Price Target | $5.00(+163.16%) |
| Earnings Date | Mar 30, 2027 |
About FBIO
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
Fortress Biotech, Inc. Stock Analysis — InsiderScore
Fortress Biotech, Inc. scored higher than 46% of companies evaluated by InsiderBuying, and ranked 43rd out of 110 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Fortress Biotech, Inc. bought $340.4K of stock across 6 purchases in the last 90 days, the largest of them $115.9K.
The average purchase added about 1% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 30, 2027Earnings report
$FBIO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in FBIO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by FBIO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
FBIO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
FBIO Revenue by Segment
| Emrosi | $9.00M | 46.99% |
| Qbrexza | $5.59M | 29.18% |
| Accutane | $3.02M | 15.78% |
| Foam franchise products (Amzeeq & Zilxi) | $942.00K | 4.92% |
| Other / legacy product revenue | $263.00K | 1.37% |
| Other revenue | $234.00K | 1.22% |
| Eurax | $105.00K | 0.55% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New FBIO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to FBIO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in FBIO
| VTIVanguard Morningstar Total Stock Market ETF | $1.06M |
| VXFVanguard Extended Market ETF | $597.30K |
| IWCiShares Micro-Cap ETF | $141.64K |
| BSVOEA Bridgeway Omni Small-Cap Value ETF | $50.00K |
| AVSCAvantis U.S. Small Cap Equity ETF | $5.26K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from FBIO’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 2026 earnings released with reported results, insider buying, and new FB-607 license deal for IBS-D treatment signals operational progress and management confidence.
Recent Insider Activity
Insider Score Trend Over Time
-0.2 since Nov 20Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BSVO | EA Bridgeway Omni Small-Cap Value ETF | 0.00% |
Weight is the stock’s share of each fund’s holdings.
